Parameter
| Biomarker | Full name | Proportion of bone marrow plasma cells>20%, M protein>20g/L, FLC ratio>20 | Molecular Type | protein/cell | |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | risk stratification and progression prediction | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow | Test Sample / Technology Platform | marrow、serum | ||
| Pathobiological Mechanisms | Abnormal indicators suggest active clonal plasma cell proliferation and increased risk of progression to symptomatic MM | ||||
| Clinical Availability Status | Clinical validation/guideline recommendation (Mayo, Spanish model) | ||||
| Notes and Dynamics | The 10-year progression rate of high-risk SMM is over 80%, and lenalidomide intervention is recommended; the new model combined with immune paralytic state (decreased uninvoloved immunoglobulin) further improves the prediction accuracy | ||||